GLP-1 coverage guide
A coverage change does not have to mean losing your progress. First identify whether you are facing a plan-wide exclusion, a prior-authorization denial, or a formulary change—then compare the options available to you.
Quick answer
Ask your plan for the denial or coverage-change reason in writing. A claim denial may be appealable; a plan-wide exclusion usually requires a different path. Manufacturer self-pay programs and physician-guided self-pay care may also be available.
Eligibility and treatment are determined by a licensed medical provider. Prescription required.
Paths to compare
Appeal, manufacturer access, or self-pay clinical care
Some employers are tightening or dropping weight-loss GLP-1 coverage as benefit costs rise. That makes it more important to understand the exact reason your access changed.
Source: Marsh, Sept. 2, 2026 ↗Start here
The language in your plan notice determines which path is most realistic.
The benefit may be excluded for everyone in the plan, even when a clinician considers treatment medically appropriate. A conventional medical-necessity appeal may not overcome an explicit benefit exclusion.
Best next move: Confirm the exclusion in the Summary Plan Description, ask when benefits are reviewed, and compare manufacturer or self-pay options.
The issue may be prior authorization, step therapy, missing documentation, a dose or drug not on the formulary, or a medical-necessity decision.
Best next move: Request the reason and criteria in writing, then ask your prescriber whether an internal appeal or alternate covered option is appropriate.
Many non-grandfathered health plans provide internal appeal rights and, in some cases, external review. Rights and deadlines vary by plan, state, and type of denial. Review CMS appeal guidance ↗
What to do next
Ask whether the change is a benefit exclusion, formulary change, prior-authorization denial, quantity limit, or step-therapy requirement.
Confirm when coverage ends, whether an existing authorization remains valid, and whether a transition fill or continuity exception may apply.
Have your current medication, dose, last injection date, time on treatment, results, side effects, prescriber information, and recent relevant labs ready.
Consider an appeal, another covered medication, manufacturer savings or self-pay access, and physician-guided self-pay telehealth care.
Do not change doses, combine products, or restart treatment on your own. A clinician should decide whether continuing, adjusting, or changing treatment is appropriate.
Compare your options
| Option | Best fit | What to confirm | Watch-outs |
|---|---|---|---|
| Insurance appeal | An individual denial involving authorization, documentation, formulary, or medical necessity | Deadline, required records, appeal levels, and external-review rights | A plan-wide exclusion may not be overturned through a standard appeal |
| Manufacturer access | Patients prescribed an FDA-approved branded medication who meet program rules | Eligible product, dose, insurance status, pharmacy channel, refill timing, and current terms | Prices and eligibility can change; starting-dose pricing may differ from maintenance doses |
| Alan Health self-pay care | People seeking online, physician-guided options without using insurance for medication | Clinical eligibility, available treatments, total plan cost, pharmacy, shipping, and ongoing support | A provider may recommend a different medication or dose; prescriptions are never guaranteed |
As of September 11, 2026, NovoCare lists a limited-time offer of $199 per month for the first two months of Wegovy® pens for eligible new patients, with standard pricing afterward. Lilly lists Zepbound® self-pay options starting at $299 per month, with price varying by dose and presentation. Always confirm current terms directly with the manufacturer.
Before your consultation
Good continuity starts with a clean handoff. These details help a provider understand where you are now and what may be appropriate next.
How Alan Health can help
Alan Health offers self-pay telehealth programs that do not require insurance for medication. A licensed provider reviews your health history and goals, determines whether treatment is appropriate, and guides your plan over time.
Start the 3-minute assessment100% online
Complete your assessment and provider consultation remotely.
Personalized review
Your clinician—not an algorithm—determines treatment eligibility.
Ongoing support
Stay connected as your response, goals, and treatment needs evolve.
Clear next steps
Understand available options before committing to a program.
Frequently asked questions
Common reasons include a plan-wide exclusion of weight-loss drugs, a formulary change, new prior-authorization rules, step therapy, quantity limits, or a change in employer benefits. Ask for the exact reason and effective date in writing.
Often, yes—especially when the denial concerns medical necessity, prior authorization, documentation, or formulary rules. A plan-wide benefit exclusion is different and may not be reversible through a standard appeal. Check your denial notice, Summary Plan Description, and applicable deadlines.
Your plan’s criteria, denial reason, clinician letter, relevant diagnoses and health history, prior treatments, clinical response, side effects, and supporting records may be relevant. Your prescriber and plan can tell you what is required for your specific case.
Possibly, but it is not automatic. A licensed provider must review your medication source, current dose, treatment gap, response, side effects, and medical history before determining the appropriate next step.
Contact your prescriber before restarting. The appropriate restart or titration plan depends on the medication, dose, length of the interruption, side effects, and your medical history.
Alan Health’s current programs are self-pay and do not require insurance for medication. Program availability, pricing, and treatment options vary, and eligibility is determined by a licensed provider.
No. Compounded drugs are not FDA-approved and are not FDA-approved generics. FDA does not review compounded drugs for safety, effectiveness, or manufacturing quality before marketing. They may be prescribed only when a licensed provider determines an available option is appropriate for an individual patient and applicable legal requirements are met.
Primary sources
Factual and pricing information last reviewed September 11, 2026. Manufacturer program terms may change.
Keep moving forward
This page is for general educational purposes and is not medical, legal, or insurance advice. Do not stop, restart, combine, or change prescription medication without speaking with a licensed medical provider. Wegovy® is a registered trademark of Novo Nordisk A/S. Zepbound® is a registered trademark of Eli Lilly and Company. Alan Health is not affiliated with or endorsed by those companies.
Compounded medications are not FDA-approved. FDA does not review compounded medications for safety, effectiveness, or manufacturing quality before marketing. An online consultation with a licensed provider is required to determine eligibility. A prescription is not guaranteed.
Alan Health Technologies, Inc.™ (d/b/a Alan Meds™ and Alan Health™) operates a patient management platform in collaboration with independently owned physician networks (including MDI Medical Group, P.C. and Alan Medical Group P.C.). Medical services are provided exclusively by licensed, independent healthcare professionals; Alan Health™ does not provide medical or pharmacy services. Prescriptions require a consultation with a licensed provider, who will assess clinical appropriateness; additional eligibility criteria may apply. Payment does not guarantee a prescription or medication dispensation. If you are experiencing a medical emergency, call 911 or go to the nearest emergency department.
Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety or effectiveness. Medication images, formulations, and packaging may differ from what is shown. Prices and promotions are subject to change and may be modified or discontinued at any time; additional terms, limits, or exclusions may apply. For certain products or services, plans may renew automatically unless canceled; cancellation terms apply. Ozempic®, Wegovy®, Mounjaro®, Zepbound®, Saxenda®, and Victoza® are trademarks of their respective owners; Alan Health™ is not affiliated with or endorsed by Novo Nordisk™, Eli Lilly and Company™, or their affiliates.
Subscribe our newsletter to get all the new updates and alerts about our fresh products
